Format

Send to

Choose Destination
Methods. 2014 Jan 1;65(1):139-47. doi: 10.1016/j.ymeth.2013.09.015. Epub 2013 Oct 1.

Engineered antibodies for molecular imaging of cancer.

Author information

1
Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. Electronic address: awu@mednet.ucla.edu.

Abstract

Antibody technology has transformed drug development, providing robust approaches to producing highly targeted and active therapeutics that can routinely be advanced through clinical evaluation and registration. In parallel, there is an emerging need to access similarly targeted agents for diagnostic purposes, including non-invasive imaging in preclinical models and patients. Antibody engineering enables modification of key properties (immunogenicity, valency, biological inertness, pharmacokinetics, clearance route, site-specific conjugation) in order to produce targeting agents optimized for molecular imaging. Expanded availability of positron-emitting radionuclides has led to a resurgence of interest and applications of immunoPET (immuno-positron emission tomography). Molecular imaging using engineered antibodies and fragments provides a general approach for assessing cell surface phenotype in vivo and stands to play an increasingly important role in cancer diagnosis, treatment selection, and monitoring of molecularly targeted therapeutics.

KEYWORDS:

Engineered antibody fragments; ImmunoPET; Positron emission tomography; Radiolabeling; Site-specific conjugation

PMID:
24091005
PMCID:
PMC3947235
DOI:
10.1016/j.ymeth.2013.09.015
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center